Academics urge updating WHO, ICH guidelines to ensure quality drugs used in clinical trials

By Zachary Brennan

- Last updated on GMT

Academics urge updating WHO, ICH guidelines to ensure quality drugs used in clinical trials

Related tags Pharmacology

The use of substandard and falsified drugs in clinical trials has been neglected and new information on product quality should be included in the GCP (good clinical practice) guidelines from the WHO and ICH, academics contend in the British Medical Journal.

Professors from the UK, US, Belgium and Thailand said in the analysis piece that there are “many different types of poor quality drugs that could mistakenly be included in clinical trials, including those with no, too little, or too much active pharmaceutical ingredient [API], those with the wrong active pharmaceutical ingredient, those with inadequate bioavailability, and those that degrade with toxic products or contaminants​.”

The authors use the example of a study from 2011 in which the antimalarial drug sulfadoxine-pyrimethamine in pregnant women in six countries in Africa was planned using four locally available brands. The products were tested at the US CDC and the sulfadoxine content of one of the brands was found to be below 90% of the manufacturer’s stated amount. An emergency request to procure a good quality brand was made and the study proceeded with confidence.

Similarly, in 2007, a consignment of clopidogrel labelled as Plavix worth £1m (€1.3m; $1.5m) for use as a comparator in a clinical trial in the US was found to be falsified. The trial was eventually able to proceed and the perpetrators were arrested.

But such studies may not always be so fortunate and the authors note that many countries, especially those in the developing world where many trials are conducted, have limited regulatory capacity for verifying bioequivalence.

Drugs containing the same stated API are not necessarily bioequivalent if they are produced by different companies or in different batches. For example, different batches of mefloquine and digoxin tablets have shown non-bioequivalence. Thus, clinical trials using different brands or batches of the same drug may give different results, which makes interpretation difficult and can dilute the power of meta-analyses that underlie many policy recommendations​,” the professors write.

The authors suggest that WHO and ICH guidelines on GCP be updated to include a requirement that states the quality of drugs and medical products, including diagnostic tests evaluated in trials or used for assessing inclusion criteria or endpoints. Batch numbers and expiry dates of drugs should also be included in trial reports and the manufacturers’ certificate of analysis should be published as supplementary material, the authors contend.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more